Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2013

Jul 26, 2013

31565_dirs_2013-07-26_b835519f-48b3-4d9a-8a75-f94ed643f1fb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2013-07-24

Reporting Person: Zane Ellen M (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-07-24 Common Stock A 1649.0 $0.0 Acquired 4397 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-07-24 Non-Qualified Stock Option (right to buy) $45.45 A 6573.0 Acquired 2023-07-24 Common Stock (6573) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Non-Qualified Stock Option (right to buy) $36.37 2019-07-27 Common Stock (10928) 10928 Direct

Footnotes

F1: Restricted Stock Unit Grant which vest 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.